|
Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
|
|
Multaq® is also under regulatory review by the European Medicines Agency (EMEA)
|
|
Read More >>
|
 |
|
Novartis Begins Shipment to US of Fluvirin(R) Influenza Virus Vaccine With Three New Strains for the 2008-2009 Influenza Season
|
|
At least 20 million doses available by the end of September
|
|
Read More >>
|
|
|
BioSante Pharmaceuticals Announces Reacquisition of Elestrin™
|
|
FDA Approved for Treatment of Hot Flashes
|
|
Read More >>
|
|
|
SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
|
|
SuperGen entitled to seven years of market exclusivity for MP-470 in the treatment of patients with GBM
|
|
Read More >>
|
|
|
SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
|
|
Submission of the ANDA is the second major SCOLR initiative this summer
|
|
Read More >>
|
|
|
Lilly Sells its Greenfield, Indiana, Operations to Covance
|
|
Expands Existing Collaboration Between the Two Companies
|
|
Read More >>
|
|
|
Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding
|
|
Xanodyne is currently targeting the submission of an NDA in early 2009
|
|
Read More >>
|
|
|
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
|
|
Mr. Krayacich brings more than 20 years of experience in pharmaceutical product development
|
|
Read More >>
|
|
|
Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc.
|
|
Stiefel Laboratories, Inc. expects to effect a merger of Bengal Acquisition Inc. with and into Barrier Therapeutics
|
|
Read More >>
|
|
|
Single-Pill Combinations Diovan HCT and Exforge Approved in US
|
|
First-Line Treatments for High Blood Pressure
|
|
Read More >>
|
|
|
Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
|
|
Company Reiterates $3.00 per Share Proposal is Best and Final Offer
|
|
Read More >>
|
|
|
U.S. FDA Issues a Not-Approvable Letter for Sugammadex
|
|
Schering-Plough acquired sugammadex through its acquisition of Organon BioSciences
|
|
Read More >>
|
|
|
Lannett Company Receives FDA Approvals for Doxycycline Tablets, 75 mg and 150 mg
|
|
Doxycycline is indicated for the treatment of bacterial infections
|
|
Read More >>
|
|
|
Taro and NextWave Announce Agreement to Co-Promote OVIDE(R) in the United States
|
|
Agreement Doubles Size of OVIDE(R) Sales Force
|
|
Read More >>
|
|
|
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
|
|
Combination Is Natural Development in Companies' Successful, Seven-Year-Long Relationship around ERBITUX®
|
|
Read More >>
|
|
|
Federal Agents Seize more than $24 Million in Unapproved New Drugs from KV Pharmaceutical Company
|
|
Products made after the FDA required an end to production
|
|
Read More >>
|
|
|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits NDA to FDA for Rivaroxaban
|
|
Filing Seeks Approval For Use in Prevention of Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Orthopedic Surgery
|
|
Read More >>
|
|
|
Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
|
|
New Delayed Release Valproate Therapy in Small, Easy-to-Swallow Soft Gel Capsule to be Available in August 2008
|
|
Read More >>
|
|
|
Shire Re-Launches ADHDSupport.com
|
|
A Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
|
|
Read More >>
|
|
|
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
|
|
Vanda plans to meet with the FDA to discuss this decision further
|
|
Read More >>
|
|
